The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer

被引:120
|
作者
Savant, Sudha S. [1 ]
Sriramkumar, Shruthi [2 ]
O'Hagan, Heather M. [1 ,3 ]
机构
[1] Indiana Univ Sch Med, Med Sci, Bloomington, IN 47405 USA
[2] Indiana Univ, Cell Mol & Canc Biol Grad Program, Bloomington, IN 47405 USA
[3] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA
关键词
inflammation; epithelial ovarian cancer; cytokines; reactive oxygen species; growth factors; ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANCHORAGE-INDEPENDENT GROWTH; FACTOR RECEPTOR EXPRESSION; INTERLEUKIN-6; SERUM-LEVELS; C-REACTIVE PROTEIN; NF-KAPPA-B; LYSOPHOSPHATIDIC ACID; CELL-PROLIFERATION;
D O I
10.3390/cancers10080251
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inflammation plays a role in the initiation and development of many types of cancers, including epithelial ovarian cancer (EOC) and high grade serous ovarian cancer (HGSC), a type of EOC. There are connections between EOC and both peritoneal and ovulation-induced inflammation. Additionally, EOCs have an inflammatory component that contributes to their progression. At sites of inflammation, epithelial cells are exposed to increased levels of inflammatory mediators such as reactive oxygen species, cytokines, prostaglandins, and growth factors that contribute to increased cell division, and genetic and epigenetic changes. These exposure-induced changes promote excessive cell proliferation, increased survival, malignant transformation, and cancer development. Furthermore, the pro-inflammatory tumor microenvironment environment (TME) contributes to EOC metastasis and chemoresistance. In this review we will discuss the roles inflammation and inflammatory mediators play in the development, progression, metastasis, and chemoresistance of EOC.
引用
收藏
页数:30
相关论文
共 50 条
  • [21] The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer
    Yang, Gong
    Xiao, Xue
    Rosen, Daniel G.
    Cheng, Xi
    Wu, Xiaohua
    Chang, Bin
    Liu, Guangzhi
    Xue, Fengxia
    Mercado-Uribe, Imelda
    Chiao, Paul
    Du, Xiang
    Liu, Jinsong
    CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2181 - 2194
  • [22] Role of myeloid cells and inflammation in cancer progression and metastasis
    Karin, Michael
    CYTOKINE, 2009, 48 (1-2) : 10 - 10
  • [23] RETRACTED ARTICLE: KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer
    Meili Pa
    Gulimire Naizaer
    Ayinuer Seyiti
    Gulina Kuerbang
    Journal of Molecular Histology, 2015, 46 : 511 - 518
  • [24] Retraction Note to: KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer
    Meili Pa
    Gulimire Naizaer
    Ayinuer Seyiti
    Gulina Kuerbang
    Journal of Molecular Histology, 2016, 47 : 103 - 103
  • [25] Lipids as mediators of cancer progression and metastasis
    Felix C. E. Vogel
    Adriano B. Chaves-Filho
    Almut Schulze
    Nature Cancer, 2024, 5 : 16 - 29
  • [26] Lipids as mediators of cancer progression and metastasis
    Vogel, Felix C. E.
    Chaves-Filho, Adriano B.
    Schulze, Almut
    NATURE CANCER, 2024, 5 (01) : 16 - 29
  • [27] Molecular physiopathology of epithelial ovarian cancer: role of inflammation
    Aceto, Gitana Maria
    Cheon, Dong-Joo
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [28] Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer
    Zhang, P.
    Zhang, P.
    Shi, B.
    Zhou, M.
    Jiang, H.
    Zhang, H.
    Pan, X.
    Gao, H.
    Sun, H.
    Li, Z.
    CELL DEATH & DISEASE, 2014, 5 : e991 - e991
  • [29] Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer
    P Zhang
    P Zhang
    B Shi
    M Zhou
    H Jiang
    H Zhang
    X Pan
    H Gao
    H Sun
    Z Li
    Cell Death & Disease, 2014, 5 : e991 - e991
  • [30] Chronic inflammatory mediators enhance prostate cancer development and progression
    Thapa, Dinesh
    Ghosh, Rita
    BIOCHEMICAL PHARMACOLOGY, 2015, 94 (02) : 53 - 62